Literature DB >> 12687465

Effective tacrolimus treatment in a child suffering from severe nephrotic syndrome.

Marco Pennesi, Ambra Gagliardo, Silvia Minisini.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12687465     DOI： 10.1007/s00467-003-1098-0

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  6 in total

1.  Tacrolimus treatment for steroid- and cyclosporin-resistant minimal-change nephrotic syndrome.

Authors:  F Schweda; R Liebl; G A Riegger; B K Krämer
Journal:  Nephrol Dial Transplant       Date:  1997-11       Impact factor: 5.992

2.  Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetil.

Authors:  M Chandra; M Susin; C Abitbol
Journal:  Pediatr Nephrol       Date:  2000-03       Impact factor: 3.714

3.  Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome.

Authors:  J McCauley; R Shapiro; D Ellis; H Igdal; A Tzakis; T E Starzl
Journal:  Nephrol Dial Transplant       Date:  1993       Impact factor: 5.992

4.  A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome.

Authors:  C Ponticelli; G Rizzoni; A Edefonti; P Altieri; E Rivolta; S Rinaldi; L Ghio; E Lusvarghi; R Gusmano; F Locatelli
Journal:  Kidney Int       Date:  1993-06       Impact factor: 10.612

5.  Levamisole treatment in steroid-sensitive and steroid-resistant nephrotic syndrome.

Authors:  K Tenbrock; J Müller-Berghaus; A Fuchshuber; D Michalk; U Querfeld
Journal:  Pediatr Nephrol       Date:  1998-08       Impact factor: 3.714

6.  Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group.

Authors: 
Journal:  Lancet       Date:  1994-08-13       Impact factor: 79.321
  6 in total
  5 in total

1.  Tacrolimus is an alternative therapy option for the treatment of adult steroid-resistant nephrotic syndrome: a prospective, multicenter clinical trial.

Authors:  Li Fan; Qinghua Liu; Yunhua Liao; Zhibin Li; Yulian Ji; Zhenhua Yang; Jian Chen; Junzhou Fu; Jinli Zhang; Yaozhong Kong; Ping Fu; Tanqi Lou; Zhengrong Liu; Xueqing Yu; Wei Chen
Journal:  Int Urol Nephrol       Date:  2012-06-09       Impact factor: 2.370

2.  Tacrolimus for children with refractory nephrotic syndrome: a one-year prospective, multicenter, and open-label study of Tacrobell®, a generic formula.

Authors:  Eun Mi Yang; Sang Taek Lee; Hyun Jin Choi; Hee Yeon Cho; Joo Hoon Lee; Hee Gyung Kang; Young Seo Park; Hae Il Cheong; Il-Soo Ha
Journal:  World J Pediatr       Date:  2015-12-18       Impact factor: 2.764

Review 3.  Off-label use of tacrolimus in children with glomerular disease: Effectiveness, safety and pharmacokinetics.

Authors:  Guo-Xiang Hao; Lin-Lin Song; Dong-Feng Zhang; Le-Qun Su; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Br J Clin Pharmacol       Date:  2020-01-14       Impact factor: 4.335

4.  Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome.

Authors:  Kim Loeffler; Manjula Gowrishankar; Verna Yiu
Journal:  Pediatr Nephrol       Date:  2004-02-03       Impact factor: 3.714

Review 5.  History of Nephrotic Syndrome and Evolution of its Treatment.

Authors:  Abhijeet Pal; Frederick Kaskel
Journal:  Front Pediatr       Date:  2016-05-30       Impact factor: 3.418
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.